Drug intelligence / Profile preview

isoalantolactone

Development stage
Preclinical
Modality
Small Molecules
Administration
In Vitro, In Vivo (research Use; No Human Administration Route Established)
01

Overview

**Isoalantolactone** is a natural sesquiterpene lactone of the eudesmanolide group, predominantly isolated from the roots of Inula helenium and other plants of the Asteraceae family[1][2]. It exhibits a broad range of pharmacological activities, including antitumor (notably proliferation inhibition, cell cycle arrest, ROS overproduction, apoptosis induction), anti-inflammatory (via NF-κB inhibition), antimicrobial, antihelminthic, antioxidant, and neuroprotective properties[1][3][5]. Mechanistically, isoalantolactone is known to induce apoptosis in cancer cells (for example, pancreatic cancer) by increasing reactive oxygen species and inhibiting the Wnt-β-catenin pathway as well as the AMPK-Skp2-Akt axis[3]. Its principal molecular pharmacodynamic actions are related to the modulation of oxidative stress and inhibition of specific intracellular signaling pathways linked to cell survival and inflammation[1][3][5].

Other names
(+)-isoalantolactoneiso-alantolactonisohelenin
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)GSK3 (Glycogen synthase kinase 3 beta)RELA (Nuclear Factor Kappa B Subunit p65)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)mTOR (Mammalian target of rapamycin kinase)AMPK (Adenosine monophosphate–activated protein kinase)SKP2

Beyond the preview

Go deeper on isoalantolactone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoalantolactone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call